76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Vaxart Inc
Closed
0.32 -23.81
Overview
Share price change
24h
Min
0.32
Max
0.32
Income | -3.6M -16M |
|---|---|
Sales | 5.7M 21M |
Profit margin | -74.684 |
Employees | 105 |
EBITDA | -3.6M -12M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +1400% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | 7.4M 100M |
|---|---|
Previous open | 24.13 |
Previous close | 0.32 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Vaxart Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vaxart Inc Forecast
Price Target
By TipRanks
1400% upside
12 Months Forecast
Average 6 USD 1400%
High 8 USD
Low 4 USD
Based on 2 Wall Street analysts offering 12 month price targets forVaxart Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
